$ News

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

12 Health Care Stocks Moving In Wednesday's Intraday Session

Vincerx Pharma shares are trading lower after the company announced it terminated its letter of intent with Global Digital regarding a potential merger.

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Vincerx Pharma Announces That It Has Terminated Previously Announced Non-Binding Letter Of Intent With Global Digital Holdings Regarding a Potential Merger

Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending

Vincerx Pharma Plans Reverse Merger With AI Infrastructure Firm QumulusAI

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

Vincerx Pharma Enters Non-Binding LOI With QumulusAI For Reverse Merger; QumulusAI To Own 95% Of Combined Entity Valued At $285M, Vincerx At $15M; QumulusAI Or Its Designees Will Invest Up To $1.5M In The Equity Of Vincerx Prior To Closing

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258

Vincerx Pharma, Inc. Announces Reverse Stock Split

Vincerx Pharma to Be Acquired by Oqory; Vincerx to Lose Jobs, Including Executives

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Vincerx Pharma announces workforce reduction of 55%, cost-control measures